CN105936917A - GRP78 gene targeted RNA interference recombinant lentivirus vectors and construction method - Google Patents

GRP78 gene targeted RNA interference recombinant lentivirus vectors and construction method Download PDF

Info

Publication number
CN105936917A
CN105936917A CN201610254023.4A CN201610254023A CN105936917A CN 105936917 A CN105936917 A CN 105936917A CN 201610254023 A CN201610254023 A CN 201610254023A CN 105936917 A CN105936917 A CN 105936917A
Authority
CN
China
Prior art keywords
grp78
homo
plv
gene
rna interference
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610254023.4A
Other languages
Chinese (zh)
Inventor
郭佳
蒋明
于丽华
蒋韵
徐月
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUZHOU RESEARCH INSTITUTE OF TONGJI UNIVERSITY
Original Assignee
SUZHOU RESEARCH INSTITUTE OF TONGJI UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUZHOU RESEARCH INSTITUTE OF TONGJI UNIVERSITY filed Critical SUZHOU RESEARCH INSTITUTE OF TONGJI UNIVERSITY
Priority to CN201610254023.4A priority Critical patent/CN105936917A/en
Publication of CN105936917A publication Critical patent/CN105936917A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

The invention relates to construction, screening and application of GRP78 (glucose regulated protein 78) gene targeted RNA interference recombinant lentivirus vectors. With use of an RNA interference technique, aiming at different target sequences of a GRP78 gene, four lentivirus eukaryotic expression vectors for expressing siRNA in 293 cells are constructed, an interference lentivirus is obtained through co-transfecting the 293 T cells with pLv-GRP78shRNA, pMD2.G and pSPAX2 and culturing. The GRP78 gene targeted RNA interference recombinant lentivirus vectors can efficiently and specifically inhibit the expression of the GRP78 gene, and can be used for preparing related gene medicines for treating tumor.

Description

Targeting GRP78 gene RNA interference recombinant lentivirus vector and construction method thereof
Technical field
The present invention relates to targeting GRP78 (glucose regulated protein 78, GRP78) The RNA interference recombinant lentivirus vector of gene and structure thereof, belong to biomedicine technical field.
Background technology
GRP78 (glucose regulated protein 78, GRP78), also known as immunoglobulin Heavy-chain binding protein, the quality control of protein synthesis, Ca in endoplasmic reticulum2 +The regulation of stable state play extremely important Role.Research shows, deprives when anoxia, aminoacid occurs in body, protein Misfolding, Ca2 +Steady output rate, cholesterol close When becoming the multiple abnormal conditions such as limited, cell will start er stress (endoplasmic reticulum stress, ERS) reaction, with the living environment that reply is abnormal, and GRP78 plays an important role in ERS path.Meanwhile, GRP78 height table Reach in kinds of tumor cells, er stress and the living environment bearing high load capacity are fled from for tumor cell and protein closes The pressure become has important effect.Previously research [ 2-3 ] shows, adenosine (adenosine) is a kind of important cellular metabolism Product, plays apoptosis-induced effect to kinds of tumor cells.And GRP78 participate in this signal process but, above-mentioned apoptosis lead to In road, the concrete function of GRP78, the most still knows little about it.
RNA perturbation technique energy selective degradation mRNA, silencing of target genes, in the expression of post-transcriptional level suppressor gene, thus can It is used for carrying out the research of gene function and the research of drug targets.RNA interference mechanism research shows, double stranded rna molecule first by Intracellular rna enzyme Dicer be degraded into 21-23 base size small molecules interference RNA (small interfering RNA, SiRNA).SiRNA is considered as the main effects thing of RNA interference.Slow virus carrier is as one of conventional viral vector, and it is special Point is that immunogenicity is low, can infect split coil method and nondividing phase cell, self-contained fragment can be integrated into host cell gene group, And stably express siRNA, long-term inhibition of gene expression in mammal various types of cells.
Summary of the invention
The present invention provides the RNA interference recombinant viral vector structure of a kind of targeting GRP78 gene, screening and application thereof.
The present invention is based on RNA perturbation technique, and for the different target sequences of GRP78 gene, constructing four can be at 293T Expressing the slow virus carrier for expression of eukaryon pLv-GRP78shRNA of siRNA in cell, this carrier is that the slow virus of self inactivation carries Body, its signal collection of illustrative plates is shown in Fig. 1, the specific suppression GRP78 gene expression of energy.
Technical scheme is as follows:
The siRNA recombinant slow virus expression vector of a kind of targeting GRP78 gene, is to treat for tumor GRP78 gene associations Property material, slow virus be by pLv-GRP78shRNA, pMD2.G and pSPAX2 carrier cotransfection 293T cell cultivate obtain;Its In, described pLv-GRP78shRNA recombinant vector is connection double chain DNA fragment in the multiple clone site of plv-shRNA carrier Building and obtain, restriction enzyme site is BamHI and EcoRI, and described double chain DNA fragment is the one in following sequence:
(1) GRP78-homo-U1 oligonucleotide sequence 1:
Positive-sense strand: 5 ' GATCCCTTGTTGGTGGCTCGACTCGACTCGAGTCGAGTCGAGCCACCAACAAGTTT TTG3 '
Antisense strand: 5 ' AATTCAAAAACTTGTTGGTGGCTCGACTCGACTCGAGTCGAGTCGAGCCACCAACA AGG3 '
(2) GRP78-homo-U2 oligonucleotide sequence 2:
Positive-sense strand: GATCCAGATTCAGCAACTGGTTAAAGCTCGAGCTTTAACCAGTTGCTGAATCTTTT TTG
Antisense strand: AATTCAAAAAAGATTCAGCAACTGGTTAAAGCTCGAGCTTTAACCAGTTGCTGAAT CTG
(3) GRP78-homo-U3 oligonucleotide sequence 3:
Positive-sense strand: GATCCGAAATCGAAAGGATGGTTAATCTCGAGATTAACCATCCTTTCGATTTCTTT TTG
Antisense strand: AATTCAAAAAGAAATCGAAAGGATGGTTAATCTCGAGATTAACCATCCTTTCGATT TCG
(4) GRP78-homo-S4 oligonucleotide sequence 4:
Positive-sense strand: GATCCGAGCGCATTGATACTAGAAATCTCGAGATTTCTAGTATCAATGCGCTCTTT TTG
Antisense strand: AATTCAAAAAGAGCGCATTGATACTAGAAATCTCGAGATTTCTAGTATCAATGCGC TCG.
According to the present invention, the construction method of the siRNA recombinant slow virus expression vector of described targeting GRP78 gene, bag Include step as follows:
A. according to GRP78 mRNA sequence, designing synthetic dsdna fragment, described double chain DNA fragment is described GRP78- One in homo-U1, GRP78-homo-U2, GRP78-homo-U3 and GRP78-homo-U4 nucleotide sequence;
The most then it is connected to described double chain DNA fragment the multiple clone site of plv-shRNA carrier is built into pLv- GRP78shRNA recombinant vector;
The most described pLv-GRP78shRNA recombinant vector is cultivated with pMD2.G and pSPAX2 carrier cotransfection 293T cell, Obtain the recombined lentivirus vector system of targeting GRP78 gene RNA interference.
The inhibition of GRP78 gene is reflected by the recombined lentivirus vector in order to disturb targeting GRP78 gene RNA Fixed, pLv-GRP78shRNA is carried out fluorescence quantitative PCR detection destination gene expression after packaging plasmid cotransfection 293T cell Level, filters out effective interference plasmid.
Accompanying drawing explanation
Fig. 1 is Lentiviral plv-shRNA result schematic diagram in embodiment.
Fig. 2 GRP78 RNA interfering slow virus carrier wink turns 293T cell 48h picture (fluorescence, visible ray).Wherein (a) is Common light microscopic (100 ×);B () is fluorescence light microscopic (100 ×).
GRP78 expression under Fig. 3 disturbance sequence.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is expanded on further.Should be understood that these embodiments are merely to illustrate the present invention Rather than restriction the scope of the present invention.In addition, it is to be understood that after having read the content that the present invention lectures, people in the art The present invention can be made various changes or modifications by member, and these equivalent form of values fall within the application appended claims equally and limited Scope.
Main material: 293T cell is purchased from Shanghai Inst. of Cytobiology, Chinese Academy of Sciences;E. coli competent DH5 α is purchased from Beijing Quanshijin Biotechnology Co., Ltd;Slow virus carrier plv-shRNA is purchased from Clontech company, containing people U6 Promoter, encoding green fluorescent protein reporter gene;Various restriction endonuclease, T4DNA ligase and Taq DNA polymerization Enzyme is U.S.'s NEB Products;SYBR Green I q RT-PCR Mixs purchases work biotechnology service raw with Shanghai Company;Hyclone and DMEM culture fluid are purchased from Gibico company of the U.S..
The slow virus carrier of embodiment 1 targeting GRP78 gene builds
1. the design of nucleic acid oligomer and synthesis
4 interference sequence (see Table 1) of design targeting GRP78 gene (NM_005347), and synthesize corresponding single stranded DNA
Table 1 targeting GRP78 gene RNA interference sequence
Sequence names Sequence information Original position
U1 CTTGTTGGTGGCTCGACTCGA 1081
U2 AGATTCAGCAACTGGTTAAAG 1109
U3 GAAATCGAAAGGATGGTTAAT 1609
U4 GAGCGCATTGATACTAGAAAT 1669
3 ' ends of shRNA oligonucleotide are TTTTT, and as the termination signal of RNA polymerase III type promoter U6, they are 5 ' and 3 ' years old End is the restriction enzyme site of BamHI and EcoRI respectively, and the loop structure in plv-shRNA template has selected CTCGAG. Each single stranded DNA synthesis fragment is as follows:
(1) GRP78-homo-U1 oligonucleotide sequence 1:
Positive-sense strand: 5 ' GATCCCTTGTTGGTGGCTCGACTCGACTCGAGTCGAGTCGAGCCACCAACAAGTTT TTG3 '
Antisense strand: 5 ' AATTCAAAAACTTGTTGGTGGCTCGACTCGACTCGAGTCGAGTCGAGCCACCAACA AGG3 '
(2) GRP78-homo-U2 oligonucleotide sequence 2: positive-sense strand: GATCCAGATTCAGCAACTGGTTAAAGCTCGAGCTTTAACCAGTTGCTGAATCTTTTTTG
Antisense strand: AATTCAAAAAAGATTCAGCAACTGGTTAAAGCTCGAGCTTTAACCAGTTGCTGAAT CTG
(3) GRP78-homo-U3 oligonucleotide sequence 3:
Positive-sense strand: GATCCGAAATCGAAAGGATGGTTAATCTCGAGATTAACCATCCTTTCGATTTCTTT TTG
Antisense strand: AATTCAAAAAGAAATCGAAAGGATGGTTAATCTCGAGATTAACCATCCTTTCGATT TCG
(4) GRP78-homo-S4 oligonucleotide sequence 4:
Positive-sense strand: GATCCGAGCGCATTGATACTAGAAATCTCGAGATTTCTAGTATCAATGCGCTCTTT TTG
Antisense strand: AATTCAAAAAGAGCGCATTGATACTAGAAATCTCGAGATTTCTAGTATCAATGCGC TCG.
2. nucleic acid oligomer annealing
By the nucleic acid oligomer of synthesis respectively with without enzyme water dissolution, concentration is 20 μMs.Take corresponding positive-sense strand and antisense strand solution, according to Following proportioning preparation annealing reaction system
Component Volume (μ L)
Annealing buffer 5
Positive-sense strand (20 μMs) 5
Antisense strand (20 μMs) 5
Water is to final volume 50
PCR instrument makes annealing treatment according to following program: 95 DEG C of 5min; 85℃ 5min; 75℃ 5min; 70 ℃5 min;4 DEG C of preservations.
3.pl-shRNA vector linearization
Take 2 μ g plv-shRNA carriers, carry out enzyme action process according to following system:
Component Volume (μ L)
10 × buffer 5
BamHI 1
EcoRI 1
Water is to final volume 50
37 DEG C of enzyme action 1 hour, 1.5% sepharose electrophoresis, use DNA purification kit to reclaim, nucleic acid-protein concentration analyzer measures Reclaim quality.
The structure of 4.plv-GRP78-shRNA carrier
Utilize T4DNA ligase, carry out carrier coupled reaction according to following system:
Component Volume (μ L)
10 × T4 connects buffer 2
Carrier recovery 2
shDNA 2
T4DNA ligase 1
Water is to final volume 20
20 DEG C connect overnight, convert matter big pumping rod bacterium competence DH5 α, select positive colony and send to order-checking.The product that this step obtains Thing is plv-GRP78-shRNA.
Embodiment 2 RNA interference turns 293T cell in slow virus wink
By 4 kinds of interference slow virus plasmids, use the method transfection 293T cell of transient transfection.293T cell uses containing 10%FBS's DMEM in high glucose culture medium, is placed in 37 DEG C, cultivates in 5%CO2 incubator.Transfect first 1 day digestion 293T cell, counting, cell is connect Plant to 35mm culture dish, each culture dish inoculation 6 × 105Individual cell;The secondary daily DMEM culture medium without FBS is prepared respectively Calcium turns reagent and RNA interference plasmid, adds 16 μ l calcium and turn reagent in every 84 μ l culture medium, adds 4 μ g matter in every 100 μ l culture medium Grain, turns solution by calcium after mixing respectively and plasmid solution mixes gently, and room temperature stands 10 minutes, is added dropwise in culture dish, 37 DEG C, in 5%CO2 incubator, cultivate 24h, change the fresh DMEM in high glucose culture medium containing 10% FBS and continue to cultivate 48h, collect Cell, extracts cell RNA.
The RT-PCR detection of the extraction of embodiment 3 total serum IgE, the synthesis of cDNA and RNA interference effect
Take 1 μ g RNA reverse transcription cDNA respectively, use the expression of fluorescence quantitative PCR method detection GRP78, with beta-actin As internal reference, the primer sequence that quantitative fluorescent PCR is used is shown in Table 2, uses 2-△ △ CT relative quantitation method to calculate different RNA The GRP78 expression of interference sequence sample.Filter out the RNA interference sequence that expression is minimum.Testing result (see figure 3) table The GRP78 gene expression dose of bright U4 sequence is minimum, illustrates that the RNA interference effect of U4 sequence is best.
Table 2.GRP78 and the design of beta-actin primed probe
Primer Sequence
F-GRP78 CCCGAGAACACGGTCTTTGA
R-GRP78 ACCACCTTGAACGGCAAGAA
F-actinb TATCGCCGCGCTCGTCGTC
R-actinb TCTTGCTCTGGGCCTCGTC
SEQUENCE LISTING
<110>Tongji University Suzhou academy
<120>targeting GRP78 gene RNA interference recombinant lentivirus vector and construction method thereof
<130> 2016
<160> 12
<170> PatentIn version 3.5
<210> 1
<211> 59
<212> DNA
<213>synthetic
<400> 1
gatcccttgt tggtggctcg actcgactcg agtcgagtcg agccaccaac aagtttttg 59
<210> 2
<211> 59
<212> DNA
<213>synthetic
<400> 2
aattcaaaaa cttgttggtg gctcgactcg actcgagtcg agtcgagcca ccaacaagg 59
<210> 3
<211> 59
<212> DNA
<213>synthetic
<400> 3
gatccagatt cagcaactgg ttaaagctcg agctttaacc agttgctgaa tcttttttg 59
<210> 4
<211> 59
<212> DNA
<213>synthetic
<400> 4
aattcaaaaa agattcagca actggttaaa gctcgagctt taaccagttg ctgaatctg 59
<210> 5
<211> 59
<212> DNA
<213>synthetic
<400> 5
gatccgaaat cgaaaggatg gttaatctcg agattaacca tcctttcgat ttctttttg 59
<210> 6
<211> 59
<212> DNA
<213>synthetic
<400> 6
aattcaaaaa gaaatcgaaa ggatggttaa tctcgagatt aaccatcctt tcgatttcg 59
<210> 7
<211> 59
<212> DNA
<213>synthetic
<400> 7
gatccgagcg cattgatact agaaatctcg agatttctag tatcaatgcg ctctttttg 59
<210> 8
<211> 59
<212> DNA
<213>synthetic
<400> 8
aattcaaaaa gagcgcattg atactagaaa tctcgagatt tctagtatca atgcgctcg 59
<210> 9
<211> 20
<212> DNA
<213>synthetic
<400> 9
cccgagaaca cggtctttga 20
<210> 10
<211> 20
<212> DNA
<213>synthetic
<400> 10
accaccttga acggcaagaa 20
<210> 11
<211> 19
<212> DNA
<213>synthetic
<400> 11
tatcgccgcg ctcgtcgtc 19
<210> 12
<211> 19
<212> DNA
<213>synthetic
<400> 12
tcttgctctg ggcctcgtc 19

Claims (3)

1. a siRNA recombinant slow virus expression vector for targeting GRP78 gene, is to treat for tumor GRP78 gene-correlation Property material, interference slow virus be by pLv-GRP78shRNA, pMD2.G and pSPAX2 carrier cotransfection 293T cell cultivate obtain; Wherein,
Described pLv-GRP78shRNA recombinant vector is connection double-stranded DNA sheet in the multiple clone site of pLv-shRNA carrier Section builds and obtains, and restriction enzyme site is BamHI and EcoRI;Described double chain DNA fragment is the one in following sequence:
(1) GRP78-homo-U1 oligonucleotide sequence 1:
Positive-sense strand:
5’GATCCCTTGTTGGTGGCTCGACTCGACTCGAGTCGAGTCGAGCCACCAACAAGTTTTTG3’
Antisense strand:
5’ AATTCAAAAACTTGTTGGTGGCTCGACTCGACTCGAGTCGAGTCGAGCCACCAACAAGG3’
(2) GRP78-homo-U2 oligonucleotide sequence 2:
Positive-sense strand: GATCCAGATTCAGCAACTGGTTAAAGCTCGAGCTTTAACCAGTTGCTGAATCTTTT TTG
Antisense strand: AATTCAAAAAAGATTCAGCAACTGGTTAAAGCTCGAGCTTTAACCAGTTGCTGAAT CTG
(3) GRP78-homo-U3 oligonucleotide sequence 3:
Positive-sense strand: GATCCGAAATCGAAAGGATGGTTAATCTCGAGATTAACCATCCTTTCGATTTCTTT TTG
Antisense strand: AATTCAAAAAGAAATCGAAAGGATGGTTAATCTCGAGATTAACCATCCTTTCGATT TCG
(4) GRP78-homo-S4 oligonucleotide sequence 4:
Positive-sense strand: chain: GATCCGAGCGCATTGATACTAGAAATCTCGAGATTTCTAGTATCAATGCGCTCTTT TTG
Antisense strand: AATTCAAAAAGAGCGCATTGATACTAGAAATCTCGAGATTTCTAGTATCAATGCGC TCG.
The construction method of the siRNA recombinant slow virus expression vector of targeting GRP78 gene the most according to claim 1,
Comprise the following steps that
A. according to GRP78 mRNA sequence, designing synthetic dsdna fragment, described double chain DNA fragment is described GRP78- One in homo-U1, GRP78-homo-U2, GRP78-homo-U3 and GRP78-homo-U4 nucleic acid sequence;
The most then it is connected to described double chain DNA fragment the multiple clone site of plv-shRNA carrier is built into pLv- GRP78shRNA recombinant vector;
The most described pLv-GRP78shRNA recombinant vector is cultivated with pMD2.G and pSPAX2 carrier cotransfection 293T cell, Obtain the recombined lentivirus vector system of targeting GRP78 gene RNA interference.
3. the siRNA recombinant slow virus expression vector of the targeting GRP78 gene described in claim 1 is correlated with in preparation treatment tumor Application in property genomic medicine.
CN201610254023.4A 2016-04-23 2016-04-23 GRP78 gene targeted RNA interference recombinant lentivirus vectors and construction method Pending CN105936917A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610254023.4A CN105936917A (en) 2016-04-23 2016-04-23 GRP78 gene targeted RNA interference recombinant lentivirus vectors and construction method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610254023.4A CN105936917A (en) 2016-04-23 2016-04-23 GRP78 gene targeted RNA interference recombinant lentivirus vectors and construction method

Publications (1)

Publication Number Publication Date
CN105936917A true CN105936917A (en) 2016-09-14

Family

ID=57151513

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610254023.4A Pending CN105936917A (en) 2016-04-23 2016-04-23 GRP78 gene targeted RNA interference recombinant lentivirus vectors and construction method

Country Status (1)

Country Link
CN (1) CN105936917A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918843A (en) * 2007-03-26 2010-12-15 南加州大学 Methods and compositions for inducing apoptosis by stimulating er stress
CN103725682A (en) * 2013-12-30 2014-04-16 深圳先进技术研究院 Small interfering ribonucleic acid (RNA) for knocking down expression of estrogen related receptor (ERR), and recombinant vector and application of RNA
CN103834691A (en) * 2014-01-21 2014-06-04 宁波大学 Construction method of target RNA-interfered recombinant lentivirus vector for IL-33 gene
CN103882058A (en) * 2012-12-24 2014-06-25 苏州中同生物科技有限公司 Construction of lentivirus recombinant shuttle vector
CN104975044A (en) * 2015-05-22 2015-10-14 浙江大学 Construction of SRSF6-targeting lentivirus interference vector and applications of SRSF6-targeting lentivirus interference vector in colorectal cancer treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918843A (en) * 2007-03-26 2010-12-15 南加州大学 Methods and compositions for inducing apoptosis by stimulating er stress
CN103882058A (en) * 2012-12-24 2014-06-25 苏州中同生物科技有限公司 Construction of lentivirus recombinant shuttle vector
CN103725682A (en) * 2013-12-30 2014-04-16 深圳先进技术研究院 Small interfering ribonucleic acid (RNA) for knocking down expression of estrogen related receptor (ERR), and recombinant vector and application of RNA
CN103834691A (en) * 2014-01-21 2014-06-04 宁波大学 Construction method of target RNA-interfered recombinant lentivirus vector for IL-33 gene
CN104975044A (en) * 2015-05-22 2015-10-14 浙江大学 Construction of SRSF6-targeting lentivirus interference vector and applications of SRSF6-targeting lentivirus interference vector in colorectal cancer treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘勇等: "稳定沉默GRP78基因的胰腺腺泡细胞株AR42J的建立", 《四川大学学报》 *
郑传宜等: "人GLUT3基因RNA干扰病毒载体的构建与鉴定", 《中南大学学报》 *

Similar Documents

Publication Publication Date Title
CN107893076A (en) CRISPR Cas9 targeting knock outs human breast cancer cell RASSF2 genes and its specific sgRNA
Lv et al. lncMGPF is a novel positive regulator of muscle growth and regeneration
KR20160145814A (en) miRNA enhancing cell productivity
Shu et al. A simplified system to express circularized inhibitors of miRNA for stable and potent suppression of miRNA functions
Chumakov et al. Efficient downregulation of multiple mRNA targets with a single shRNA-expressing lentiviral vector
US20110003883A1 (en) Allosteric trans-splicing group i ribozyme whose activity of target-specific rna replacement is controlled by theophylline
CN104031916B (en) New RNAi precursors and its preparation and application
CN108265080A (en) The human lung cancer stable cell line and its construction method of PlexinB2 gene silencings
CN101987197B (en) Method and reagent for inhibiting invasiveness of cancer cells
CN103509797B (en) A kind of microRNA and preparation method thereof and the application in the drug of specific up-regulation Gene Transcription in vitro
CN105936917A (en) GRP78 gene targeted RNA interference recombinant lentivirus vectors and construction method
CN101948859B (en) shRNA expression vector expressed by specificity inhibitor SET protein, construction method and application thereof
CN103505745A (en) Application of micromolecule RNA used as immunosuppressor
CN106480098A (en) Targeting VEGFA gene RNA interference recombinant lentivirus vector and its construction method
CN103952410B (en) The shRNA of a kind of effective suppression rat FoxO3a genetic expression and application thereof
CN102229928B (en) Small-interfering RNA (Ribonucleic Acid) of human RBBP6 (Retinoblastoma-binding Proteingene) and application thereof
CN109055429B (en) Mouse osteogenic-like cell lentiviral vector targeting RunX2 gene and construction method thereof
CN102813926B (en) Application of miR-7 expression inhibitor in preparing medicines used for treating systemic lupus erythematosus
CN111926018A (en) Application of substance for reducing USP1 expression in preparation of medicine for treating children T-line acute lymphoblastic leukemia
CN105002181B (en) A kind of rat Kif11 genes interference shRNA and its recombinant adeno-associated virus and antitumor application thereof
CN106399378A (en) PLC (phospholipase C) epsilon gene targeted RNA-interference recombinant lentiviral vectors and construction method thereof
CN105925611A (en) RNA interference recombinant lentiviral vectors targeting HSP70 gene and construction method of RNA interference recombinant lentiviral vectors
CN101993894A (en) Construction method of siRNA adenovirus carrier for restraining rat IL-1beta gene expression
CN102220377A (en) Novel interference vector for increasing animal lean meat percentage and application thereof
WO2024010028A1 (en) Circular rna molecule, and translation control method, translation activation system and pharmaceutical composition using same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160914

WD01 Invention patent application deemed withdrawn after publication